Fractional Head of GTM for Healthcare
Editorial revision: . Original publication and source dates are retained.
Use fractional commercial leadership to test a defined market and sales approach, establish an operating cadence, and specify the permanent role the business needs next.
Return to insightsHealthcare founders and CEOs who need senior GTM operating leverage before the next permanent executive hire. / Evergreen framework
The strategic question
When does fractional GTM leadership create leverage instead of becoming another advisory layer?
I use fractional commercial leadership to resolve an expensive uncertainty before the company commits to a permanent organization. The uncertainty might be the buyer, the sale’s true duration, the implementation burden or the commercial leader the business actually needs. The mandate should state which decision will become possible because of the engagement. A calendar of meetings is not that decision.
The economics are those of a bounded investment in information and execution. Compare the engagement’s cost with the cost of committing early to the wrong segment, channel or senior hire. That comparison supports a finite scope and a decision date; it does not justify an indefinite advisory retainer. A founder with a validated market and an execution bottleneck may need a permanent accountable leader immediately. A founder still changing the product after every sales call has a different problem.
The assignment also needs real authority. I would agree who can change account priorities, qualify an opportunity out, negotiate within approved boundaries and require product or delivery resources. Responsibility without those rights produces commentary on the pipeline instead of a commercial result. Authority must remain bounded by clinical, legal, financial and contractual approval requirements.
Operating model
Use a finite mandate to resolve a permanent commitment.
The work should distinguish evidence of demand from evidence of repeatability. An introduction to a friendly buyer can test the problem. A signed pilot can test willingness to fund a defined experiment. A successfully implemented, renewed engagement can test a larger part of the business model. Those are different milestones, and a fractional leader should not compress them into a single claim of traction.
I would organize the mandate around a small number of live opportunities that expose the difficult interfaces: budget authority, procurement, information security, implementation and the receiving team’s capacity. Record why each deal advances or stops. The useful output is an account of the market that another executive can act on, supported by observed decisions and a service the company can deliver.
At the decision date, compare committed revenue, implementation cost, gross contribution, sales effort and time to cash with the original assumptions. If demand is real but delivery remains bespoke, fund product and implementation discipline before adding sellers. If the sales process repeats and founder dependence is falling, define the permanent role around the remaining constraint. If the buyer will not fund the problem, a recommendation to stop can preserve more value than a larger unqualified pipeline.
Operating framework
- 01
Set a decision date and spending ceiling around the market, delivery or hiring uncertainty the mandate must resolve.
- 02
Specify the segment, live opportunities, decision rights and implementation resources available to the leader.
- 03
Test whether funded demand, contribution and delivery can repeat without continuing founder intervention.
- 04
Commit to a permanent role only when the remaining constraint and its accountable owner are clear.
Metrics that matter
- 01
Cost and time to the agreed investment or hiring decision
- 02
Funded opportunities with verified authority and delivery capacity
- 03
Expected contribution after selling and implementation expense
- 04
Commercial steps repeatable without founder intervention
Red flags
The retainer continues without a decision date, cost ceiling or evidence that uncertainty is being resolved.
Pipeline grows while delivery remains bespoke and contribution after implementation remains unknown.
The engagement recommends more selling capacity before identifying the constraint a permanent leader would own.
CEO and CFO questions
Which irreversible commitment are we deferring, and what evidence would justify making it?
Can the next customer be acquired and served at acceptable contribution without exceptional founder effort?
At the decision date, does the remaining constraint require a commercial hire, delivery investment or a change in market?
Discuss the strategic decision